{"product_id":"gsk-bcg-matrix","title":"GSK Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe GSK BCG Matrix offers a powerful framework for understanding the company's diverse product portfolio. By categorizing products into Stars, Cash Cows, Dogs, and Question Marks, it provides a clear visual representation of market share and growth potential. This initial glimpse highlights key areas for strategic focus, but for a truly actionable understanding, the full matrix is essential.\u003c\/p\u003e\n\u003cp\u003eDive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Medicines Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGSK's Specialty Medicines portfolio is a powerhouse, showing a robust 17% sales jump in Q1 2025 and a strong 19% growth throughout 2024. This segment is crucial for GSK's expansion, particularly in oncology, HIV, and respiratory\/immunology. \u003c\/p\u003e\n\u003cp\u003eThe company anticipates this high-performing division to maintain its momentum, projecting continued low double-digit percentage growth. This sustained success solidifies GSK's leadership in vital, expanding therapeutic markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJemperli (dostarlimab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJemperli, an oncology treatment, experienced a remarkable tripling of its sales in 2024, largely driven by new FDA approvals. This substantial sales increase signifies a growing presence in the competitive oncology sector, positioning Jemperli as a strong performer within GSK's product lineup.\u003c\/p\u003e\n\u003cp\u003eThe drug's broadening application to new cancer types further solidifies its status as a star, suggesting ongoing strong sales and market penetration for GSK.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabenuva (cabotegravir + rilpivirine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCabenuva, a long-acting injectable HIV treatment, is a significant contributor to GSK's robust HIV franchise. Its innovative dosing schedule provides a distinct advantage in the expanding HIV treatment landscape, positioning it as a star product with both high growth potential and a substantial market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApretude (cabotegravir)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eApretude, GSK's innovative long-acting injectable for HIV pre-exposure prophylaxis (PrEP), demonstrated exceptional market performance. In 2024, its sales experienced a remarkable surge of approximately 90%, underscoring its growing adoption and impact in HIV prevention.\u003c\/p\u003e\n\u003cp\u003eGSK is strategically investing in expanding Apretude's supply chain, with a clear objective to triple annual doses by the 2025-2026 period. This aggressive expansion signals strong confidence in the product's significant market potential and its robust growth trajectory within the prevention sector.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eApretude's 2024 sales growth: Approximately 90% increase.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSupply expansion target: Triple annual doses by 2025-2026.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMarket position: Key driver for future HIV segment growth.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGSK's oncology portfolio is a star performer within its business structure.  This segment saw an impressive 53% sales increase in the first quarter of 2025.  Furthermore, the oncology business nearly doubled its sales throughout 2024, showcasing exceptional momentum.\u003c\/p\u003e\n\u003cp\u003eThis significant growth is fueled by GSK's commitment to developing cutting-edge cancer therapies and making strategic investments in this area. The robust performance firmly places the oncology portfolio in the high-growth category, indicating expanding market share and strong future potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eOncology Sales Growth (Q1 2025):\u003c\/strong\u003e 53% increase.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOncology Sales Growth (2024):\u003c\/strong\u003e Nearly doubled.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Drivers:\u003c\/strong\u003e Innovative therapies and strategic investments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePortfolio Status:\u003c\/strong\u003e High-growth area with increasing market penetration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Medicines: High Growth \u0026amp; Market Dominance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGSK's Specialty Medicines segment, particularly oncology and HIV treatments, represents its Stars in the BCG matrix. These products exhibit high growth and strong market share, driving significant revenue increases. For instance, Apretude, an HIV prevention drug, saw about a 90% sales surge in 2024, with plans to triple doses by 2025-2026. Similarly, Jemperli, an oncology treatment, tripled its sales in 2024 due to new approvals. The overall oncology business nearly doubled its sales in 2024, highlighting its star status.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\/Segment\u003c\/td\u003e\n\u003ctd\u003e2024 Sales Growth\u003c\/td\u003e\n\u003ctd\u003eKey Drivers\u003c\/td\u003e\n\u003ctd\u003eMarket Position\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty Medicines\u003c\/td\u003e\n\u003ctd\u003e19%\u003c\/td\u003e\n\u003ctd\u003eOncology, HIV, Respiratory\/Immunology\u003c\/td\u003e\n\u003ctd\u003eHigh Growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJemperli (Oncology)\u003c\/td\u003e\n\u003ctd\u003eTripled\u003c\/td\u003e\n\u003ctd\u003eNew FDA Approvals\u003c\/td\u003e\n\u003ctd\u003eStrong Performer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCabenuva (HIV)\u003c\/td\u003e\n\u003ctd\u003eSignificant Contributor\u003c\/td\u003e\n\u003ctd\u003eLong-acting injectable, innovative dosing\u003c\/td\u003e\n\u003ctd\u003eStar Product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApretude (HIV PrEP)\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003ctd\u003eLong-acting injectable, expanding supply\u003c\/td\u003e\n\u003ctd\u003eKey Growth Driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology Portfolio\u003c\/td\u003e\n\u003ctd\u003eNearly Doubled\u003c\/td\u003e\n\u003ctd\u003eInnovative therapies, strategic investments\u003c\/td\u003e\n\u003ctd\u003eHigh-Growth Category\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe GSK BCG Matrix analyzes its product portfolio by market share and growth, guiding investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eQuickly identify underperforming \"Dogs\" and \"Cash Cows\" needing strategic attention, relieving the pain of wasted resources.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShingrix (shingles vaccine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShingrix, GSK's shingles vaccine, continues to be a powerful cash cow, bringing in £3.176 billion in revenue in 2024. Despite some market adjustments and age-related sales shifts seen in late 2024 and early 2025, the vaccine maintains a commanding market presence. \u003c\/p\u003e\n\u003cp\u003eThis strong market share translates into consistent and significant cash flow for GSK. The company anticipates Shingrix will remain a vital revenue driver for the foreseeable future, underscoring its importance within GSK's product portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucala (mepolizumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNucala, a key product in GSK's respiratory and immunology portfolio, achieved significant revenue of £1.570 billion in 2024. This strong performance was fueled by the addition of new approved uses for the drug.\u003c\/p\u003e\n\u003cp\u003eWhile Nucala experienced robust growth, with a 28% increase in Q1 2025, its status as an established product in a market that is reaching maturity positions it as a dependable cash generator for GSK.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDovato (dolutegravir + lamivudine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDovato, a key HIV treatment from GSK, is a prime example of a Cash Cow within the company's portfolio.  In 2024, it generated impressive sales of £1.3 billion, underscoring its significant market presence and profitability. \u003c\/p\u003e\n\u003cp\u003eIts established efficacy and strong patient adherence contribute to consistently high-profit margins, making it a reliable source of substantial cash flow for GSK. This consistent performance solidifies its position as a mature, high-performing product. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrelegy Ellipta (fluticasone furoate + umeclidinium + vilanterol)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTrelegy Ellipta stands out as a significant Cash Cow for GSK, holding the distinction of being the most prescribed single inhaler triple therapy for both COPD and asthma globally. Its impressive market penetration is underscored by robust sales growth, which reached 27% in 2024 and continued at a strong 15% in the first quarter of 2025. This consistent demand in a well-established respiratory market translates into a reliable and substantial source of cash flow for the company.\u003c\/p\u003e\n\u003cp\u003eThe sustained performance of Trelegy Ellipta is a testament to its established efficacy and market position. This product's ability to generate consistent revenue makes it a cornerstone of GSK's portfolio, contributing significantly to its financial stability and ability to fund other ventures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Leadership:\u003c\/strong\u003e Trelegy Ellipta is the world's leading single inhaler triple therapy for COPD and asthma.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrong Sales Growth:\u003c\/strong\u003e Achieved 27% sales growth in 2024 and 15% in Q1 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMature Market Dominance:\u003c\/strong\u003e Continues to generate substantial and steady cash in a mature respiratory market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Revenue Driver:\u003c\/strong\u003e Its consistent demand solidifies its role as a major cash generator for GSK.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBenlysta (belimumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBenlysta, GSK's immunology treatment, showed robust performance with 14% growth in 2024. This indicates its continued strength and market relevance in the autoimmune disease space.\u003c\/p\u003e\n\u003cp\u003eAs a Cash Cow in the BCG matrix, Benlysta benefits from a mature market position, ensuring a stable and significant contribution to GSK's specialty medicines revenue stream. Its established market share translates into predictable and substantial profit margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eBenlysta's 2024 growth:\u003c\/strong\u003e 14% increase in sales.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket position:\u003c\/strong\u003e Established and dominant in its therapeutic area.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue contribution:\u003c\/strong\u003e Consistent and significant to GSK's specialty medicines portfolio.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProfitability:\u003c\/strong\u003e High profit margins due to mature market status and low reinvestment needs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHow Established Products Drive Financial Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash Cows represent products with high market share in mature, low-growth industries, generating more cash than they consume. GSK's portfolio features several such products, contributing significantly to its financial stability.\u003c\/p\u003e\n\u003cp\u003eThese established products, like Shingrix and Trelegy Ellipta, benefit from strong brand recognition and consistent demand. Their mature market status means lower reinvestment needs, allowing them to be reliable sources of substantial cash flow for GSK.\u003c\/p\u003e\n\u003cp\u003eThis consistent revenue generation enables GSK to fund research and development for new products and invest in other strategic areas. The dependable performance of these Cash Cows is crucial for the company's overall financial health and growth strategy.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Revenue (approx.)\u003c\/th\u003e\n\u003cth\u003eKey Growth Driver\u003c\/th\u003e\n\u003cth\u003eMarket Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eShingrix\u003c\/td\u003e\n\u003ctd\u003e£3.176 billion\u003c\/td\u003e\n\u003ctd\u003eDominant market presence\u003c\/td\u003e\n\u003ctd\u003eMature, high demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNucala\u003c\/td\u003e\n\u003ctd\u003e£1.570 billion\u003c\/td\u003e\n\u003ctd\u003eNew approved uses, strong growth\u003c\/td\u003e\n\u003ctd\u003eMature, dependable generator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDovato\u003c\/td\u003e\n\u003ctd\u003e£1.3 billion\u003c\/td\u003e\n\u003ctd\u003eEstablished efficacy, patient adherence\u003c\/td\u003e\n\u003ctd\u003eMature, high profit margins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrelegy Ellipta\u003c\/td\u003e\n\u003ctd\u003eSignificant growth (27% in 2024)\u003c\/td\u003e\n\u003ctd\u003eGlobal leadership in respiratory\u003c\/td\u003e\n\u003ctd\u003eMature, consistent demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBenlysta\u003c\/td\u003e\n\u003ctd\u003e14% growth in 2024\u003c\/td\u003e\n\u003ctd\u003eStrong market relevance in immunology\u003c\/td\u003e\n\u003ctd\u003eMature, stable contribution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eGSK BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe GSK BCG Matrix preview you're examining is the definitive document you'll receive upon purchase, offering a complete and unwatermarked strategic analysis. This comprehensive report, meticulously prepared, will be delivered directly to you, ready for immediate application in your business planning. You can be confident that the insights and formatting you see here are precisely what you'll get, enabling swift and informed decision-making. This is your direct access to a professionally crafted tool designed to illuminate GSK's product portfolio and guide strategic resource allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArexvy (RSV vaccine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArexvy, GSK's respiratory syncytial virus (RSV) vaccine, faces a challenging position within the BCG matrix.  Despite a robust initial market entry, its sales experienced a significant downturn, dropping 51% in 2024 and a further 57% in the first quarter of 2025. \u003c\/p\u003e\n\u003cp\u003eThis sharp decline is attributed to revised Centers for Disease Control and Prevention (CDC) recommendations and heightened competition within the vaccine sector.  Such a rapid loss of market traction suggests Arexvy is struggling to maintain its growth trajectory and profitability, potentially shifting it towards a question mark or even a dog in the BCG framework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeretide\/Advair (fluticasone propionate + salmeterol)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeretide\/Advair, a cornerstone respiratory medication from GSK, is now positioned as a Dog in the BCG Matrix.  Its market share has been significantly eroded by a growing wave of generic alternatives, leading to a steady decline in sales.  \u003c\/p\u003e\n\u003cp\u003eIn 2023, GSK reported that its respiratory segment, which includes Seretide\/Advair, saw a decline in sales, a trend exacerbated by the increasing availability and adoption of generics.  This product now represents a low-growth, low-market-share asset, likely contributing minimal net cash to the company's overall financial health.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlovent\/Flixotide (fluticasone propionate)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFlovent\/Flixotide, containing fluticasone propionate, are established inhaled corticosteroids that, much like Advair, face significant pressure from generic competition. Their market position is increasingly challenged by newer, more advanced respiratory treatments, leading to declining sales and a diminished market share.\u003c\/p\u003e\n\u003cp\u003eThese factors firmly place Flovent\/Flixotide in the ‘Dog’ category of GSK's BCG Matrix. In 2023, the global market for inhaled corticosteroids, while substantial, saw a slowdown in growth for older molecules, with the fluticasone propionate segment experiencing a low single-digit decline in certain developed markets due to pricing pressures and the availability of generics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVentolin (salbutamol)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVentolin, a salbutamol-based rescue inhaler, exemplifies a classic 'Dog' in GSK's BCG Matrix. Its market is highly mature, characterized by extensive generic competition and significant price pressures. \u003c\/p\u003e\n\u003cp\u003eWhile Ventolin remains a widely recognized and utilized medication for asthma relief, its revenue contribution is likely diminished due to its low market share in value terms. The growth prospects for this established product are minimal, reflecting the saturated nature of the rescue inhaler market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eLow Market Share (Revenue):\u003c\/strong\u003e Ventolin's revenue share is likely depressed due to generic erosion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLow Market Growth:\u003c\/strong\u003e The rescue inhaler market offers little expansion potential for older, established brands.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCapital Tie-up:\u003c\/strong\u003e Continued investment in marketing or production for Ventolin may yield low returns.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Consideration:\u003c\/strong\u003e GSK may consider divesting or minimizing investment in Ventolin to reallocate resources to higher-growth products.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZantac Litigation Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Zantac litigation has placed a significant financial strain on GSK, exemplified by the substantial £1.8 billion charge incurred in 2024. This ongoing liability, stemming from a product divested years ago, functions as a cash trap, diverting vital resources away from growth initiatives. \u003c\/p\u003e\n\u003cp\u003eThis situation aligns with the characteristics of a 'Dog' in the BCG matrix; it consumes capital without generating revenue or contributing to the company's future expansion. The £1.8 billion charge in 2024 underscores the persistent financial burden, highlighting how past issues can significantly impact current financial health and strategic flexibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eZantac Litigation:\u003c\/strong\u003e A financial drain with a £1.8 billion charge in 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCash Trap:\u003c\/strong\u003e Non-revenue generating liabilities consuming company resources.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBCG Matrix 'Dog':\u003c\/strong\u003e Reflects a business unit with low market share and low growth prospects, consuming cash.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImpact on GSK:\u003c\/strong\u003e Diverts capital from growth areas due to historical product issues.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK's \"Dogs\": Low Growth, High Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProducts classified as Dogs in GSK's BCG Matrix represent business units with low market share in a low-growth industry. These products typically generate low profits or even losses, often requiring more cash to maintain than they produce. GSK's strategy for these products usually involves minimizing investment or considering divestment to free up resources for more promising ventures.\u003c\/p\u003e\n\u003cp\u003eFor instance, Seretide\/Advair, a former star product, has become a Dog due to intense generic competition, leading to declining sales. Similarly, Ventolin, a widely used rescue inhaler, operates in a saturated market with significant price pressures, limiting its growth potential and revenue contribution.\u003c\/p\u003e\n\u003cp\u003eThe Zantac litigation, despite not being a product in the traditional sense, acts as a 'Dog' by consuming significant capital without generating revenue. GSK incurred a substantial £1.8 billion charge in 2024 related to this issue, highlighting how such liabilities can drain resources and hinder strategic flexibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\/Issue\u003c\/td\u003e\n\u003ctd\u003eBCG Category\u003c\/td\u003e\n\u003ctd\u003eMarket Growth\u003c\/td\u003e\n\u003ctd\u003eMarket Share\u003c\/td\u003e\n\u003ctd\u003eFinancial Impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeretide\/Advair\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eDeclining\u003c\/td\u003e\n\u003ctd\u003eReduced Revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVentolin\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eLow (Value Terms)\u003c\/td\u003e\n\u003ctd\u003eMinimal Contribution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZantac Litigation\u003c\/td\u003e\n\u003ctd\u003eDog (Liability)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e£1.8 Billion Charge (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlenrep (belantamab mafodotin)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBlenrep, a treatment for multiple myeloma, is positioned as a potential Star in GSK's BCG Matrix. Following its recent re-approval in the European Union for combination therapies, and with anticipated FDA approval in 2025, Blenrep is poised for significant growth. Analysts project peak sales to surpass £2 billion, highlighting its high growth potential within the crucial oncology market.\u003c\/p\u003e\n\u003cp\u003eDespite its promising future, Blenrep currently occupies a low market share. This is largely attributed to its recent re-entry into the market and the ongoing phases of its launch. As GSK ramps up its commercialization efforts, Blenrep's market share is expected to increase, solidifying its Star status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDepemokimab\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDepemokimab, a promising new treatment for severe asthma and chronic rhinosinusitis with nasal polyps, is positioned as a potential future star within GSK's portfolio.  Its long-acting anti-IL5 antibody mechanism targets a significant unmet need in the respiratory market.\u003c\/p\u003e\n\u003cp\u003eWith an anticipated FDA approval in 2025 and projected peak sales exceeding £2 billion, Depemokimab represents a substantial growth opportunity. However, as a pipeline asset awaiting full commercial launch, its current market share is negligible, placing it in the question mark category of the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlujepa (gepotidacin)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBlujepa (gepotidacin) represents a promising new entrant in GSK's portfolio, positioned as a potential star or question mark within the BCG matrix. Its recent FDA approval in Q1 2025 for uncomplicated urinary tract infections, coupled with a priority review for gonorrhea, highlights its innovative nature and addresses critical unmet needs in infectious diseases. This suggests substantial future growth prospects.\u003c\/p\u003e\n\u003cp\u003eWhile Blujepa's novel mechanism of action and broad spectrum of activity point towards high market potential, its current market share is understandably small given its recent launch. As it gains traction and navigates market adoption, its position will evolve, requiring careful monitoring of sales performance and competitive landscape to determine if it transitions into a star or remains a question mark requiring further investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePenmenvy (meningitis vaccine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePenmenvy, a new meningococcal B vaccine, received FDA approval in the first quarter of 2025. This positions it to enter a vaccine market projected to grow significantly, with analysts forecasting a compound annual growth rate (CAGR) of 7.5% for the global meningitis vaccine market through 2030, reaching an estimated $7.2 billion.  Penmenvy's innovative formulation and broad coverage offer high potential for adoption and market share capture, especially given the increasing incidence of meningococcal disease outbreaks.\u003c\/p\u003e\n\u003cp\u003eHowever, Penmenvy is currently in the early stages of its commercial rollout, meaning its market presence is limited. This limited initial presence places it in the question mark category of the BCG matrix. Its future success will depend on its ability to gain traction against established competitors and demonstrate clear clinical and economic advantages.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Entry:\u003c\/strong\u003e FDA approval in Q1 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Potential:\u003c\/strong\u003e High, within a growing vaccine market (estimated 7.5% CAGR through 2030).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCurrent Status:\u003c\/strong\u003e Limited market presence due to recent commercial rollout.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBCG Classification:\u003c\/strong\u003e Question Mark, requiring strategic investment to determine future success.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltra Long-Acting HIV Regimens (e.g., VH184, VH499, N6LS)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGSK's pipeline features promising ultra long-acting HIV regimens like VH184, VH499, and N6LS. These investigational assets are positioned as significant high-growth opportunities within the dynamic HIV treatment market. \u003c\/p\u003e\n\u003cp\u003eWhile these novel regimens show positive development data, they currently represent zero market share as they are not yet launched. Their potential lies in addressing unmet needs for more convenient HIV management.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh Growth Potential:\u003c\/strong\u003e Ultra long-acting formulations offer a paradigm shift in HIV treatment adherence and patient convenience.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestigational Status:\u003c\/strong\u003e As these are still in development, they do not contribute to current market share but represent future revenue streams.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Opportunity:\u003c\/strong\u003e The global HIV therapeutics market was valued at approximately USD 33.9 billion in 2023 and is projected to grow, with long-acting options expected to capture a significant portion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Strength:\u003c\/strong\u003e These advancements underscore GSK's commitment to innovation in addressing chronic diseases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK's Question Marks: High Potential, Early Stage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks in GSK's portfolio represent products with high growth potential but currently low market share. These are often new products or pipeline assets that require significant investment to gain market traction and determine their future success.  Effective resource allocation is crucial for these products to transition into Stars.\u003c\/p\u003e\n\u003cp\u003eGSK's strategic focus includes nurturing these Question Marks, such as Depemokimab and Blujepa, by investing in their development and commercialization. The success of these ventures will be pivotal in shaping GSK's future market leadership.\u003c\/p\u003e\n\u003cp\u003eThe company is actively managing its Question Mark portfolio, aiming to convert promising candidates into market leaders. This involves careful evaluation of market dynamics and competitive landscapes to ensure optimal investment decisions.\u003c\/p\u003e\n\u003cp\u003eSeveral key GSK products currently fall into the Question Mark category, reflecting their early-stage market presence despite significant growth potential. These include Depemokimab for severe asthma, Blujepa for urinary tract infections and gonorrhea, and Penmenvy, a meningococcal B vaccine. Additionally, GSK's ultra long-acting HIV regimens (VH184, VH499, N6LS) are also Question Marks as they are still in development.\u003c\/p\u003e\n\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eTherapeutic Area\u003c\/th\u003e\n\u003cth\u003eMarket Potential\u003c\/th\u003e\n\u003cth\u003eCurrent Market Share\u003c\/th\u003e\n\u003cth\u003eBCG Classification\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDepemokimab\u003c\/td\u003e\n\u003ctd\u003eSevere Asthma, CRS w\/ NP\u003c\/td\u003e\n\u003ctd\u003eHigh (Peak sales \u0026gt; £2bn)\u003c\/td\u003e\n\u003ctd\u003eNegligible\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlujepa (gepotidacin)\u003c\/td\u003e\n\u003ctd\u003eUTI, Gonorrhea\u003c\/td\u003e\n\u003ctd\u003eHigh (Novel mechanism)\u003c\/td\u003e\n\u003ctd\u003eSmall (Recent launch)\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePenmenvy\u003c\/td\u003e\n\u003ctd\u003eMeningococcal B Vaccine\u003c\/td\u003e\n\u003ctd\u003eHigh (7.5% CAGR in market)\u003c\/td\u003e\n\u003ctd\u003eLimited (Early rollout)\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUltra Long-Acting HIV Regimens (VH184, VH499, N6LS)\u003c\/td\u003e\n\u003ctd\u003eHIV Treatment\u003c\/td\u003e\n\u003ctd\u003eHigh (Addressing unmet needs)\u003c\/td\u003e\n\u003ctd\u003eZero (Investigational)\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098092573020,"sku":"gsk-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/gsk-bcg-matrix.png?v=1781795864","url":"https:\/\/pestel-analysis.com\/products\/gsk-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}